AstraZeneca has achieved a clinically meaningful milestone with tozorakimab's Phase 3 success in a historically difficult-to-treat COPD subpopulation, and the differentiation from failed competitor programs is a genuine competitive advantage. However, the stock's sharp single-day reaction likely prices in a favorable outcome ahead of regulatory and commercial execution that remains years away. The mixed efzimfotase alfa adult data and the active DOJ effort to dismiss AstraZeneca's drug pricing lawsuit represent meaningful downside risks that are underweighted in current market sentiment. The company's financial foundation—8% revenue growth, strong oncology franchise, and a deep pipeline—is solid, but near-term price appreciation appears to be running ahead of confirmed operational progress.